In a marketplace where brand identity often holds as much value as the product itself, the Delhi High Court’s decision in RSPL Health Pvt. Ltd. v. Sun Pharma Laboratories Ltd. (FAO (COMM) 65/2025, decided on 12 June 2025) stands as a thoughtful reminder that intellectual property law is a tool of fairness, not of control. The judgment, delivered by Justice Navin Chawla and Justice Shalinder Kaur, reaffirms that trademarks exist to protect consumers from confusion not to arm proprietors with monopolies over imagination.
Background of the Case
RSPL Health Pvt. Ltd., proprietor of the trademark “PRO-EASE,” asserts exclusive rights to its use in connection with sanitary napkins and hygiene products since 2012. Meanwhile, Sun Pharma Laboratories Ltd., a prominent pharmaceutical company in India, has been marketing a medicinal product under the brand name “PRUEASE” since 2017. This product contains ‘Prucalopride’ and is indicated for the treatment of constipation.
RSPL Health Pvt. Ltd. filed a petition before the Commercial Court at Patiala House, New Delhi, seeking an interim injunction under Order XXXIX Rule 1 and 2 of the Civil Procedure Code (CPC) to restrain Sun Pharma Laboratories Ltd. from using the mark “PRUEASE.” RSPL contended that “PRUEASE” was phonetically and visually similar to its registered trademark “PRO-EASE,” thereby creating a likelihood of confusion among consumers. In response, Sun Pharma argued that the respective products sanitary napkins and a prescription medication for constipation belonged to entirely distinct categories, making confusion improbable. Sun Pharma further asserted that its mark was adopted in good faith, being a combination of “Prucalopride” the active pharmaceutical ingredient, and the word “Ease” to convey therapeutic relief.
On 15 February 2025, the Commercial Court refused to grant injunction, holding that there was no realistic possibility of confusion. RSPL’s appeal before the Delhi High Court under Section 13 of the Commercial Courts Act, 2015 met the same fate.
Observations of the Commercial Court
The Commercial Court held that the goods in question were fundamentally distinct in terms of their nature, purpose, and target consumers. It opined that a personal hygiene product and a pharmaceutical formulation intended for medical treatment were unlikely to be confused by the average consumer. The Court further emphasized that the respective products operated within separate trade channels sanitary napkins being sold through general retail outlets, while the prescription medicine was dispensed via pharmacies under medical supervision.
Sun Pharma’s continuous use of the mark “PRUEASE” since 2017 was supported by documentary evidence, whereas RSPL’s usage was limited to sanitary napkins. The Court found that Sun Pharma’s adoption of the mark was bona fide and descriptive, reflecting a logical derivation from the active ingredient, Prucalopride, combined with the term “Ease” to denote therapeutic relief. Consequently, the Court concluded that RSPL had not demonstrated a prima facie case for injunction, and that the balance of convenience lay in favour of Sun Pharma.
Observations of Delhi High Court
The Delhi High Court upheld the trial court’s reasoning, relying on Wander Ltd. v. Antox India Pvt. Ltd. 1990 Supp SCC 727 to reiterate that an appellate court should not interfere with a discretionary order unless it is manifestly arbitrary or perverse. The Bench held that no confusion was conceivable between a sanitary product and a constipation medicine both occupied entirely different commercial ecosystems.
The Court emphasised that registration in a broad class does not grant ownership over all goods within that class. Citing Nandhini Deluxe v. Karnataka Milk Federation (2018) 9 SCC 183, it held that trademark protection must relate to the proprietor’s actual trade activity and not a hypothetical expansion. RSPL’s argument of having a “right to expand” into pharmaceuticals was rejected as speculative and unsupported by evidence.
The Court further noted that, as the appeal was instituted under ‘Section 13’ of the Commercial Courts Act, 2015, the appellate jurisdiction was limited in scope. It clarified that interference was permissible only in cases involving jurisdictional lapses or manifest errors, and that appellate courts are not empowered to re-evaluate discretionary determinations or reappraise evidence in interlocutory proceedings.
The Court also underscored the duty of full disclosure in seeking equitable relief. RSPL’s omission to reveal Sun Pharma’s prior user affidavit before the Trademark Registry weakened its case. Recognising that “PRUEASE” had been coined logically from the chemical ingredient and its intended effect, the Court found honest and descriptive adoption, not imitation. The appeal was accordingly dismissed on 12 June 2025.
Critical Analysis
The judgment in RSPL Health Pvt. Ltd. v. Sun Pharma Laboratories Ltd. reflects a balanced and realistic interpretation of trademark law. The Court rightly limited protection to genuine cases of consumer confusion, reaffirming that trademarks exist to prevent deception, not to create monopolies. By refusing injunction, the Court drew a sensible distinction between legal rights and commercial realities.
The recognition that “PRUEASE” was a bona fide and descriptive mark derived from a drug’s chemical composition shows judicial appreciation for scientific and linguistic necessity in pharmaceutical branding. The insistence on actual use over speculative expansion prevents overreach by proprietors who attempt to dominate an entire class of goods without trading in them.
At the same time, the Court’s emphasis on transparency noting RSPL’s nondisclosure of relevant documents reinforces the clean hands doctrine, essential to equitable remedies. While the decision strengthens market fairness, it also raises a subtle concern: that a high threshold for “likelihood of confusion” might make it harder to address brand dilution across unrelated sectors. Nevertheless, the ruling upholds the integrity of trademark law pragmatic, proportionate, and rooted in common sense.
Conclusion
This case is more than a routine trademark dispute it is a judicial statement that law must evolve with commerce and common sense. The High Court’s refusal to grant injunction is a reminder that a trademark’s strength lies not in its registration, but in its real-world identity and purpose.
In essence, the judgment humanises trademark jurisprudence. It recognises that legal protection must be balanced with honest competition, that science deserves linguistic freedom, and that the law’s role is not to protect power, but to preserve fairness.
Summarized by: Ms. Ritika Agarwal, BA LLB -2021-2026, LLOYD Law Collage, Noida